A complete breakdown of pharmaceutical contract manufacturing in India, covering CMO vs CDMO, how to pick the right partner, and what’s changing in 2026, including region-specific insights for Himachal Pradesh.
Baddi is quietly responsible for over a third of India’s total drug formulation output. This piece unpacks why this Himachal Pradesh pharma company hub outgrew every other industrial belt in the country, how it compares to Hyderabad and Gujarat, and what sponsors should actually verify before signing with a Baddi-based manufacturing partner.
Learn how pharma contract manufacturing helps pharmaceutical brands reduce costs, scale production, ensure regulatory compliance, and accelerate market entry in 2026.
India has some genuinely strong oncology medicine manufacturers, but they’re not all built the same. Here’s what actually matters when you’re trying to find a credible partner in cancer drug manufacturing.
India’s CDMO sector is growing fast, and for good reason. But not every partner is built the same. Here’s a practical, no-jargon guide to understanding what CDMO companies in India actually offer and how to choose wisely.
CDMO stands for Contract Development and Manufacturing Organization. But knowing the full form is just the starting point. Here’s what CDMOs actually do, why they matter in pharma, and how they’re different from CMOs and CROs.
OEB Level-5 is the highest occupational safety classification in pharmaceutical manufacturing. It is required for cytotoxic oncology APIs and HPAPI compounds where airborne worker exposure must stay below 1 microgram per cubic metre of air. A genuinely certified facility needs ...
For most pharma companies, a CDMO partnership is significantly cheaper than building in-house. An in-house oncology manufacturing facility costs USD 150M–500M+ to build, takes 3–5 years to reach the first commercial batch, and carries full utilisation risk on your balance ...
To select the right oncology CDMO, evaluate seven criteria in this order: regulatory approvals (USFDA, MHRA, EU-GMP, ANVISA), OEB Level-5 containment certification, end-to-end oncology services, technology transfer track record, manufacturing capacity, BIOSECURE Act supply chain compliance, and quality culture. Always ...
There is a question every pharma company building an oncology pipeline eventually has to answer honestly: do we build this manufacturing capability ourselves, or do we find someone who already has it? Building it yourself means years of facility construction, ...